NEW YORK (GenomeWeb) – Silence Therapeutics this week announced the publication of preclinical data showing that its acute lung injury drug Atu111 could reduce the severity of sepsis-related illness and improve survival in mice.
The finding appeared in Critical Care Medicine.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.